8-K filed April 21, 2026, 7:59 PM ET ticker JATT CIK 0002112446

other material confidence high sentiment neutral materiality 0.80

JATT II Acquisition Corp closes $60M IPO; shares trade on Nasdaq under 'JATT'

JATT II Acquisition Corp.

Priced 6,000,000 ordinary shares at $10.00 per share; gross proceeds $60M.
Concurrently sold 300,000 private placement shares to sponsor JATT Ventures II L.P. for $3M.
Guggenheim Securities LLC acted as sole book-runner; 45-day over-allotment option for up to 900,000 additional shares.
$60M placed in trust account; funds held until business combination or 24-month deadline.
Appointed four independent directors and established audit, compensation, and nominating committees.

item 1.01 item 3.02 item 5.02 item 5.03 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-26-045819
form_type: 8-K
ticker: JATT
cik: 0002112446
company_name: JATT II Acquisition Corp.
filed_at: 2026-04-21T23:59:59+00:00
discovered_at: 2026-05-14T18:02:33.502209+00:00
generated_at: 2026-05-15T05:11:43.282119+00:00
sec_items: ["1.01", "3.02", "5.02", "5.03", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-26-045819
json_url: https://secwatch.observer/filing/0001213900-26-045819.json
markdown_url: https://secwatch.observer/filing/0001213900-26-045819.md
text_url: https://secwatch.observer/filing/0001213900-26-045819.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/2112446/000121390026045819/0001213900-26-045819-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/2112446/000121390026045819/ea0287066-8k_jatt2.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

5df2ed4bca817d76e17ec465fa1d252f66d3d6e8

JATT II Acquisition Corp. entered into Registration Rights Agreement with JATT Ventures II L.P. and Holders valued at Registration Rights Agreement among the Company, Sponsor and Holders (effective 2026-04-16).

A Registration Rights Agreement, dated April 16, 2026, among the Company, the Sponsor and the Holders signatory thereto, a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.

SEC 8-K Item 1.01/1.02 confidence 0.95 SEC evidence

6f9ab7cf1c4459fd38044fa8183abbb62f7b0a5b

JATT II Acquisition Corp. entered into Private Placement Shares Purchase Agreement with JATT Ventures II L.P. valued at Private Placement Shares Purchase Agreement between the Company and Sponsor (effective 2026-04-16).

A Private Placement Shares Purchase Agreement, dated April 16, 2026 (the “ Private Placement Shares Purchase Agreement ”), between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 hereto and incorporated herein by reference.

SEC 8-K Item 1.01/1.02 confidence 0.95 SEC evidence

8b96e08341f258a6af9cfd55eaa8e2168982df1d

JATT II Acquisition Corp. entered into Letter Agreement with JATT Ventures II L.P. and officers and directors valued at Letter Agreement among the Company, sponsor, and officers/directors (effective 2026-04-16).

A Letter Agreement, dated April 16, 2026 (“ Letter Agreement ”), among the Company, the Company’s sponsor, JATT Ventures II L.P. (the “ Sponsor ”) and each of the officers and directors of the Company, a copy of which is attached as Exhibit 10.1 hereto and incorporated herein by reference.

SEC 8-K Item 1.01/1.02 confidence 0.85 SEC evidence

9a355d6333042045edcff893c88ccf4ed1f10f58

JATT II Acquisition Corp. entered into Underwriting Agreement with Guggenheim Securities, LLC valued at Underwriting Agreement for IPO of 6,000,000 ordinary shares at $10.00 per share (effective 2026-04-16).

An Underwriting Agreement, dated April 16, 2026, between the Company and Guggenheim Securities, LLC, a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference.

SEC 8-K Item 1.01/1.02 confidence 0.95 SEC evidence

9ac499949f63348c47d5ad48d94ce294b1371238

JATT II Acquisition Corp. entered into Indemnity Agreements with officers and directors valued at Indemnity Agreements between the Company and each of its officers and directors (effective 2026-04-16).

Indemnity Agreements, each dated April 16, 2026 (each, an “ Indemnity Agreement ”), between the Company and each of its officers and directors, substantially in the form attached hereto as Exhibit 10.6.

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

bf3e0031bd1bffed55cc55c9a5019865151374bd

JATT II Acquisition Corp. entered into Investment Management Trust Agreement with Continental Stock Transfer & Trust Company valued at Investment Management Trust Agreement with trustee (effective 2026-04-16).

An Investment Management Trust Agreement, dated April 16, 2026, between the Company and Continental Stock Transfer & Trust Company, as trustee, a copy of which is attached as Exhibit 10.2 hereto and incorporated herein by reference.

SEC 8-K Item 1.01/1.02 confidence 0.95 SEC evidence

Comparable filings

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

A Registration Rights Agreement, dated April 16, 2026, among the Company, the Sponsor and the Holders signatory thereto, a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.

Comparable filing

A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent

Filing page SEC filing

SAGU

Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE

Shreya Acquisition Group May 11, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

A Registration Rights Agreement, dated April 16, 2026, among the Company, the Sponsor and the Holders signatory thereto, a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.

Comparable filing

Private Units Subscription Agreement, dated May 6, 2026, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 and incorporated herein by reference

Filing page SEC filing

SUJA

Suja Life completes IPO of 8.9M shares at $21/share; closes May 8, 2026

SUJA LIFE, INC. May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 3.03, 5.03, 5.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 5.02, 5.03, 9.01 same event type: other_material similar materiality

This filing

A Registration Rights Agreement, dated April 16, 2026, among the Company, the Sponsor and the Holders signatory thereto, a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.

Comparable filing

On May 6, 2026, Suja Life, Inc. (the “Company”) and Suja Life Holdings, L.P. (“Holdings LP”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Jefferies LLC, and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”) relating to the initial public offering (the “IPO”) of the Company’s Class A common stock

Filing page SEC filing

CLRB

Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data

Cellectar Biosciences, Inc. May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 8.01, 9.01 same event type: other_material similar materiality

This filing

A Registration Rights Agreement, dated April 16, 2026, among the Company, the Sponsor and the Holders signatory thereto, a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.

Comparable filing

pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”

Filing page SEC filing

TPST

Tempest Therapeutics enters warrant exercise inducement for ~$2M; issues new warrants to purchase 2.34M shares at $1.73

Tempest Therapeutics, Inc. June 1, 2026, 7:13 PM ET other_material Items 1.01, 3.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 9.01 same event type: other_material similar materiality

This filing

A Registration Rights Agreement, dated April 16, 2026, among the Company, the Sponsor and the Holders signatory thereto, a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.

Comparable filing

On May 28, 2026, Tempest Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a warrant exercise and inducement offer letter agreement (the “ Inducement Letter ”) with a holder of certain existing warrants to purchase shares of the Company’s common stock

Filing page SEC filing

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 8.01, 9.01 same event type: other_material similar materiality

This filing

A Registration Rights Agreement, dated April 16, 2026, among the Company, the Sponsor and the Holders signatory thereto, a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.

Comparable filing

On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).

Filing page SEC filing

XRN

Chiron Real Estate enters $100M preferred equity deal with Maewyn XRN LP

Chiron Real Estate Inc. May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 9.01 same event type: other_material similar materiality

This filing

A Registration Rights Agreement, dated April 16, 2026, among the Company, the Sponsor and the Holders signatory thereto, a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.

Comparable filing

In connection with the Private Placement, on May 6, 2026, the Company and the Purchasers entered an Investor Rights Agreement.

Filing page SEC filing

NKTR

Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO

NEKTAR THERAPEUTICS May 8, 2026, 7:59 PM ET other_material Items 1.01, 5.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 5.02, 9.01 same event type: other_material similar materiality

This filing

A Registration Rights Agreement, dated April 16, 2026, among the Company, the Sponsor and the Holders signatory thereto, a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.

Comparable filing

On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.

Filing page SEC filing

Source: SEC EDGAR

accession 0001213900-26-045819

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.